Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci140 in Advanced Solid Tumors
NCT07251166Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of GenSci140 in solid tumor (advanced stage), ovarian cancer, endometrial cancer (EC) and 2 more (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events at 3 weeks, Dose Limiting Toxicities at 3 weeks and 5 more. Started Dec 2025; status: recruiting.
02
Drugs
GenSci140
03
Conditions
solid tumor (advanced stage)ovarian cancerendometrial cancer (EC)lung cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07251166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251166.